Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations
NCT03191149Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2018
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoint: Best Objective Response Rate at 5 years. Started Apr 2018; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03191149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03191149.